Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants with Bullous Pemphigoid
- Conditions
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- argenx
- Target Recruit Count
- 98
- Registration Number
- NCT05267600
- Locations
- 🇺🇸
Investigator site 121 - US0010092, Redwood City, California, United States
🇺🇸Investigator site 115 - US0010157, Jackson, Mississippi, United States
🇺🇸Investigator site 34 - US0010182, Houston, Texas, United States
Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis
- Conditions
- Interventions
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2022-02-21
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 200
- Registration Number
- NCT05247554
Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial
- Conditions
- Interventions
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 34
- Registration Number
- NCT05223582
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 4
- Registration Number
- NCT05211336
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 49
- Registration Number
- NCT05201248
- Locations
- 🇨🇳
Tianjin Cancer Hospital /ID# 228135, Tianjin, Tianjin, China
🇨🇳Peking University Third Hospital /ID# 228138, Beijing, Beijing, China
🇨🇳The Fifth Medical Center of PLA General Hospital /ID# 230520, Beijing, Beijing, China
Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT05188911
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT05157971
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Ozurdex Monotherapy Trial
- Conditions
- Interventions
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 84
- Registration Number
- NCT05101928
- Locations
- 🇨🇦
Ottawa Hospital Research Institute - Vision Research Centre, Ottawa, Ontario, Canada
Pre-operative Steroids in CRSsP
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Loma Linda University
- Registration Number
- NCT05095961
Pediatric GVHD Low Risk Steroid Taper Trial
- Conditions
- Interventions
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- John Levine
- Target Recruit Count
- 50
- Registration Number
- NCT05090384
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸Boston Children's Hospital Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.